Last reviewed · How we verify

Atezolizumab Injection [Tecentriq]

Nykode Therapeutics ASA · FDA-approved active Small molecule

Atezolizumab Injection [Tecentriq] is a PD-L1 inhibitor Small molecule drug developed by Nykode Therapeutics ASA. It is currently FDA-approved for Metastatic non-small cell lung cancer (NSCLC), Metastatic urothelial carcinoma, Small cell lung cancer (SCLC). Also known as: Tecentriq, RO5541267.

Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity.

Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity. Used for Metastatic non-small cell lung cancer (NSCLC), Metastatic urothelial carcinoma, Small cell lung cancer (SCLC).

At a glance

Generic nameAtezolizumab Injection [Tecentriq]
Also known asTecentriq, RO5541267
SponsorNykode Therapeutics ASA
Drug classPD-L1 inhibitor
TargetPD-L1
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Atezolizumab binds to programmed death ligand 1 (PD-L1), preventing its interaction with PD-1 and B7.1 receptors on T cells. This blockade restores T-cell activation, proliferation, and anti-tumor function. By inhibiting the PD-L1/PD-1 axis, the drug enhances the body's natural immune response against cancer cells.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Atezolizumab Injection [Tecentriq]

What is Atezolizumab Injection [Tecentriq]?

Atezolizumab Injection [Tecentriq] is a PD-L1 inhibitor drug developed by Nykode Therapeutics ASA, indicated for Metastatic non-small cell lung cancer (NSCLC), Metastatic urothelial carcinoma, Small cell lung cancer (SCLC).

How does Atezolizumab Injection [Tecentriq] work?

Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity.

What is Atezolizumab Injection [Tecentriq] used for?

Atezolizumab Injection [Tecentriq] is indicated for Metastatic non-small cell lung cancer (NSCLC), Metastatic urothelial carcinoma, Small cell lung cancer (SCLC), Hepatocellular carcinoma, Breast cancer (triple-negative).

Who makes Atezolizumab Injection [Tecentriq]?

Atezolizumab Injection [Tecentriq] is developed and marketed by Nykode Therapeutics ASA (see full Nykode Therapeutics ASA pipeline at /company/nykode-therapeutics-asa).

Is Atezolizumab Injection [Tecentriq] also known as anything else?

Atezolizumab Injection [Tecentriq] is also known as Tecentriq, RO5541267.

What drug class is Atezolizumab Injection [Tecentriq] in?

Atezolizumab Injection [Tecentriq] belongs to the PD-L1 inhibitor class. See all PD-L1 inhibitor drugs at /class/pd-l1-inhibitor.

What development phase is Atezolizumab Injection [Tecentriq] in?

Atezolizumab Injection [Tecentriq] is FDA-approved (marketed).

What are the side effects of Atezolizumab Injection [Tecentriq]?

Common side effects of Atezolizumab Injection [Tecentriq] include Fatigue, Decreased appetite, Nausea, Cough, Dyspnea, Immune-mediated pneumonitis.

What does Atezolizumab Injection [Tecentriq] target?

Atezolizumab Injection [Tecentriq] targets PD-L1 and is a PD-L1 inhibitor.

Related